Belderbos José S A, Kepka Lucyna, Spring Kong Feng-Ming, Martel Mary K, Videtic Gregory M M, Jeremic Branislav
Department of Radiation Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):335-42. doi: 10.1016/j.ijrobp.2008.04.081.
Lymphatic spread is an important pathway of progression in non-small-cell lung cancer (NSCLC), along with local spread and distant metastasis. The probability of lymph node (LN) involvement is dependent on the site of the primary tumor, stage, and histology. Elective nodal irradiation (ENI) is the irradiation of clinical and radiological uninvolved LN to account for microscopic tumor invasion in these LNs because we have not been able to determine the extent of LN spread accurately. The clinical value of ENI is uncertain. The impact of ENI is dependent on many (staging-, treatment-, and patient-related) factors. The purpose of this report is to analyze the current status of ENI and to provide comprehensive in-depth analysis and guidance on how to generally approach this issue in NSCLC.
淋巴转移是非小细胞肺癌（NSCLC）进展的重要途径，与局部扩散和远处转移一样。淋巴结（LN）受累的概率取决于原发肿瘤的部位、分期和组织学类型。选择性淋巴结照射（ENI）是对临床和影像学未受累的LN进行照射，以考虑这些LN中的微观肿瘤浸润，因为我们无法准确确定LN转移的范围。ENI的临床价值尚不确定。ENI的影响取决于许多（分期、治疗和患者相关）因素。本报告的目的是分析ENI的现状，并就如何在NSCLC中普遍处理这一问题提供全面深入的分析和指导。
